Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
In millions, except per share items | Sep-30-22 | Sep-05-22 | Sep-30-21 | Sep-05-21 | Sep-30-20 | Sep-30-19 | Sep-30-18 | Sep-30-17 |
| 10-K | 8-K | 10-K | 8-K | 10-K | 10-K | 10-K | 10-K |
Revenues: |
Medtronic | | | | | | | 13.0 | 13.2 |
Other | | | | | | | 68.3 | 60.0 |
Total revenues [+] | 100.0 | 100.0 | 105.1 | 105.1 | 94.9 | 100.1 | 81.3 | 73.1 |
Royalties | | 36.2 | | 47.1 | | | | |
Products | | 54.6 | | 46.5 | | | | |
Revenue growth [+] | -4.9% | -4.9% | 10.8% | | -5.2% | 23.0% | 11.2% | 2.4% |
Medtronic | | | | | | | -1.1% | -26.2% |
Cost of goods sold | 20.3 | 20.3 | 17.2 | 17.2 | 15.3 | 13.6 | 14.0 | 11.4 |
Gross profit | 79.6 | 79.6 | 88.0 | 88.0 | 79.5 | 86.4 | 67.3 | 61.7 |
Gross margin | 79.6% | 79.6% | 83.7% | 83.7% | 83.9% | 86.4% | 82.8% | 84.4% |
Selling, general and administrative | 50.6 | 46.9 | 46.7 | 30.7 | 50.2 | 24.0 | 24.1 | 20.5 |
Research and development | 50.6 | | 46.7 | | 50.2 | 52.9 | 41.0 | 31.8 |
Other operating expenses | 0.6 | 54.8 | -12.0 | 50.6 | -19.4 | 2.2 | 3.2 | 2.3 |
EBITDA [+] | -13.0 | -13.0 | 14.5 | 14.7 | 5.8 | 14.7 | 5.5 | 12.7 |
EBITDA growth | -189.6% | -188.0% | 150.2% | | -60.4% | 165.8% | -56.4% | -49.2% |
EBITDA margin | -13.0% | -13.0% | 13.8% | 14.0% | 6.1% | 14.7% | 6.8% | 17.3% |
Depreciation | 4.7 | 9.1 | 4.9 | 8.0 | 4.8 | 4.7 | 3.7 | 3.0 |
EBITA | -17.8 | -22.1 | 9.6 | 6.7 | 1.1 | 10.0 | 1.8 | 9.7 |
EBITA margin | -17.8% | -22.1% | 9.2% | 6.4% | 1.1% | 10.0% | 2.2% | 13.3% |
Amortization of intangibles | 4.4 | | 3.1 | | 2.5 | 2.6 | 2.7 | 2.6 |
EBIT [+] | -22.2 | -22.1 | 6.5 | 6.7 | -1.4 | 7.4 | -0.9 | 7.1 |
EBIT growth | -439.6% | -429.7% | -550.4% | | -119.7% | -907.8% | -112.8% | -64.6% |
EBIT margin | -22.2% | -22.1% | 6.2% | 6.4% | -1.5% | 7.4% | -1.1% | 9.7% |
Non-recurring items [+] | | | | | | 0.9 | 7.9 | |
In-process research & development | | | | | | 0.9 | 7.9 | |
Interest income, net [+] | | | | | | 0.9 | 0.9 | 0.4 |
Interest expense | | | | | | 0.2 | | |
Interest income | | | | | | 1.1 | 0.9 | 0.4 |
Other income (expense), net [+] | -0.3 | -0.4 | -0.2 | -0.4 | 0.0 | 0.1 | 0.4 | -0.5 |
Gain (loss) on foreign currency transactions | | | | | | 0.1 | 0.2 | -0.5 |
Other | -0.3 | | -0.2 | | 0.0 | | | |
Pre-tax income | -22.5 | -22.5 | 6.3 | 6.3 | -1.5 | 7.6 | -7.5 | 7.0 |
Income taxes | 4.8 | 4.8 | 2.1 | 2.1 | -2.6 | 0.0 | -3.1 | 3.1 |
Tax rate | | | 33.2% | 33.2% | 177.2% | | 40.8% | 44.2% |
Net income | -27.3 | 0.0 | 4.2 | 0.0 | 1.1 | 7.6 | -4.5 | 3.9 |
Net margin | -27.3% | 0.0% | 4.0% | 0.0% | 1.2% | 7.6% | -5.5% | 5.4% |
|
Basic EPS [+] | ($1.96) | $0.00 | $0.31 | $0.00 | $0.08 | $0.57 | ($0.34) | $0.30 |
Growth | -736.7% | | 271.5% | | -85.4% | -267.4% | -213.5% | -61.1% |
Diluted EPS [+] | ($1.96) | $0.00 | $0.30 | $0.00 | $0.08 | $0.55 | ($0.34) | $0.29 |
Growth | -747.1% | | 272.5% | | -85.2% | -262.6% | -215.5% | -61.2% |
|
Shares outstanding (basic) [+] | 13.9 | 13.9 | 13.8 | 13.8 | 13.6 | 13.4 | 13.2 | 13.2 |
Growth | 1.1% | 1.1% | 1.6% | | 1.2% | 1.8% | 0.0% | 1.2% |
Shares outstanding (diluted) [+] | 13.9 | 13.9 | 14.0 | 13.8 | 13.8 | 13.8 | 13.2 | 13.4 |
Growth | -0.5% | 1.1% | 1.3% | | 0.2% | 4.7% | -1.7% | 1.3% |
|
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|